       In The News
 Rib-X Pharmaceuticals - 2011 Fierce 15 By John Carroll
The Scoop: This has been a big year for Rib-X. The biotech started off 2011 with a $20 million venture round, followed by a breakthrough partnership with Sanofi ($SNY)--which is betting Rib-X's scientific work can get it back in the antibiotic business.  Rib-X inks potentially lucrative deal with Sanofi for new class of antibiotics By Donna Young
Rib-X Pharmaceuticals' Nobel Prize-winning crystallography technology caught the attention of several drug makers in the past year, but Sanofi was the first to win the rights to it in pursuing development and commercialization of a new class of antibiotics under a deal that could potentially be worth more than $772 million to the small biotech.  Rib-X Raises Another $20M, Led by Warburg Pincus, to Develop Late Stage Antibiotics By Luke Timmerman
New Haven, CT-based Rib-X Pharmaceuticals has rounded up another sizable investment to carry out its antibiotic R&D. The company said today it has raised $20 million in a financing led by Warburg Pincus, the giant private equity firm.  Financings of the Fortnight Will Sell No Wine Before Its Time
Rib-X Pharmaceuticals: Antibiotic developer Rib-X said Jan. 11 it has raised a $20 million round led by longtime investor Warburg Pincus, mainly to fund a 240-patient Phase 2b trial of its lead product delafloxacin against standards of care linezolid and vancomycin.  Antibiotic Dust Settling, but Regulatory Questions Remain By Trista Morrison
If there was one topic that dominated conversations at last week’s Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), it was recent signs of regulatory stability in the tumultuous antibiotics fi eld. After years of debate over endpoints and noninferiority margins, it appears the dust is beginning to settle.  Drug-Resistant Gram-Negative Bugs Draw Attention at ICAAC By Trista Morrison
There's so much going on at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that it’s difficult to focus on one subject. That said, recent regulatory progress in the antibiotics field had a lot of folks talking, according Mark Leuchtenberger, president and CEO of Rib-X Pharmaceuticals Inc.  The skinny on endpoints By Erin McCallister
FDA draft guidance issued last month on clinical development of candidates to treat acute bacterial skin and skin structure infections better reflects clinical practice than the standards that have previously been used for approval. Companies contacted by BioCentury said the guidance provides much needed clarity on the agency’s expectations.
|
